Gelesis is a biotherapeutics company advancing a novel hydrogel platform technology to treat obesity, help with weight management, and other chronic metabolic diseases.

Register for Details

For more details on financing and valuation for Gelesis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Gelesis's ticker symbol?

GLS

What is Gelesis's stock price?

0.1586 as of 4/10/23

Gelesis Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
7/19/2020 Series Growth 3 $100.49MM raised $XXX.XX $XXX.XX
2/28/2018 Series Growth 2 $30.37MM raised $XXX.XX $XXX.XX
12/30/2015 Series Growth $31.5MM raised $XXX.XX $XXX.XX
3/26/2015 Series A-5 $24.54MM raised $XXX.XX $XXX.XX
5/16/2014 Series A-4 $5.47MM raised $XXX.XX $XXX.XX
1/3/2008 Series A-1, A-2 and A-3 $14.78MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Gelesis

Forge green plus iconForge green minus icon

What is Gelesis funding to date?

Gelesis has raised $207.14MM to date.
Forge green plus iconForge green minus icon

When was Gelesis founded?

Gelesis was founded in 2006.
Updated on: Jun 12, 2022